Interventions for Tuberculosis Control and Elimination 2002
Interventions for Tuberculosis Control and Elimination 2002
Interventions for Tuberculosis Control and Elimination 2002
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
593. Hawken M, Nunn P, Gathua S, Brindle R, Godfrey-Faussett P, Githui W,<br />
Odhiambo J, Batchelor B, Gilks C, Morris J, McAdam K. Increased recurrence<br />
of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993; 342: 332-7.<br />
594. Perriens JH, Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, Portaels F,<br />
Willame JC, M<strong>and</strong>ala JK, Kaboto M, Ryder RW, Roscigno G, Piot P. Pulmonary<br />
tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment <strong>for</strong><br />
either 6 or 12 months. N Engl J Med 1995; 332: 779-84.<br />
595. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of<br />
tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir<br />
Crit Care Med 1998; 158: 157-61.<br />
596. Centers <strong>for</strong> Disease <strong>Control</strong> <strong>and</strong> Prevention. Prevention <strong>and</strong> treatment of tuberculosis<br />
among patients infected with human immunodeficiency virus: principles of<br />
therapy <strong>and</strong> revised recommendations. Morb Mortal Wkly Rep 1998; 47(No. RR-<br />
20): 1-58.<br />
597. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin<br />
monoresistance in patients with HIV-related tuberculosis treated with once-weekly<br />
rifapentine <strong>and</strong> isoniazid. Lancet 1999; 353: 1843-7.<br />
598. Rieder HL, Arnadottir T, Trébucq A, Enarson DA. <strong>Tuberculosis</strong> treatment: dangerous<br />
regimens? (Counterpoint). Int J Tuberc Lung Dis 2001; 5: 1-3.<br />
599. Fitzgerald DW, Desvarieux M, Svere P, Joseph P, Johnson WD, Jr, Pape JW.<br />
Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-<br />
1-infected individuals: a r<strong>and</strong>omised trial. Lancet 2000; 356: 1470-4.<br />
600. World Health Organization. Anti-tuberculosis drug resistance in the world. Report<br />
No. 2. WHO/CDS/TB/2000.278: Geneva: WHO, 2000: 1-117.<br />
601. Tanzania Medical Research Council, British Medical Research Council. <strong>Control</strong>led<br />
clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary<br />
tuberculosis. Am Rev Respir Dis 1985; 131: 727-31.<br />
602. Swai OB, Aluoch JA, Githui WA, Thiong’o R, Edwards EA, Darbyshire JH,<br />
Nunn AJ. <strong>Control</strong>led clinical trial of a regimen of two durations <strong>for</strong> the treatment<br />
of isoniazid resistant pulmonary tuberculosis. Tubercle 2000; 69: 5-14.<br />
603. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to<br />
short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;<br />
133: 423-30.<br />
604. Enarson DA. Principles of IUATLD Collaborative <strong>Tuberculosis</strong> Programmes.<br />
Bull Int Union Tuberc Lung Dis 1991; 66: 195-200.<br />
605. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J,<br />
Kochi A, Dye C, Raviglione MC. St<strong>and</strong>ard short-course chemotherapy <strong>for</strong> drugresistant<br />
tuberculosis. Treatment outcomes in 6 countries. JAMA 2000; 283:<br />
2537-45.<br />
209
Change language